As a company, we value the fact that all patients are unique and deserve individual treatments tailored specifically for them. We strive to constantly improve current drug therapies realizing that there is no one right dose for all patients. Our aim is to provide individualized treatments for patients, with improved outcomes.
Baysient® develops SaaS, cloud-based software that provides medical providers with a full line of individual dosage-determination products for both small molecule drugs and biologics to facilitate individualized and improved treatment outcomes for inflammatory diseases such as IBD, RA, etc. Baysient’s software uses Bayesian models, routine lab results, and demographic information to allow physicians to individualize dosing to a specific target trough level.
Baysient is the only company that has conducted prospective clinical trials that confirm superior outcomes in patients dosed using this technology and reduced the incidence of anti-drug antibodies. Through extensive clinical trials, our individual dosage-determination products have demonstrated substantial and statistically significant real-world benefits both for safety and efficacy. Our technology is patented and utilizes quality standards that are referenced by the FDA. The Baysient system can be used with or without therapeutic drug monitoring.
Vision
The variations seen in the individual pharmacokinetics of biologics inspired us to create an integrative, cloud-based software based on Bayesian models. Utilizing these models, along with routine lab results and demographic information, our software allows physicians to individualize dosing to a specific target trough level. These treatment plans yield a significantly lower incidence of anti-drug antibodies and, subsequently, significantly more patients in remission.
Values
All patients are unique and deserve individual treatments tailored specifically for them. There is no one-size-fits-all when it comes to treating inflammatory diseases, especially when it comes to drug dosing. Every patient has a right to a personalized treatment approach that is specifically designed to work for them.
Mission
Our mission is to provide individualized treatments for patients to improve the efficacy of inflammatory disease treatment. Due to the high variability in clearance between anti-TNF monoclonals among individuals and different clinical conditions, the need for personalized dosing is high. By focusing on important, modifiable factors for regulating drug levels, we can improve patient outcomes in clinical settings.
Baysient is the only company that has conducted prospective clinical trials that confirm superior outcomes in patients dosed using this technology and reduced the incidence of anti-drug antibodies. Through extensive clinical trials, our individual dosage-determination products have demonstrated substantial and statistically significant real-world benefits both for safety and efficacy. Our technology is patented and utilizes quality standards that are referenced by the FDA. The Baysient system can be used with or without therapeutic drug monitoring.
Taking the Hell out of Healthcare ™
Schedule a Demo
Interested in how iDose® can improve your patient outcomes?
